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Abstract
Free Water Imaging is a novel diffusion magnetic reasonance imaging (MRI) method that is able 
to separate changes affecting the extracellular space from those that reflect changes in neuronal 
cells and processes. A previous Free Water Imaging study in schizophrenia identified significantly 
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greater extracellular water volume in the early stages of the disorder; however, it’s clinical and 
functional sequelae have not yet been investigated. Here, we applied Free Water Imaging to a 
larger cohort of 63 first-episode patients with psychosis and 70 healthy matched controls to better 
understand the functional significance of greater extracellular water. We used diffusion MRI data 
and the Tract-Based Spatial Statistics analytic pipeline to first analyze fractional anisotropy (FA), 
the most commonly employed metric for assessing white matter. This comparison was then 
followed by Free Water Imaging analysis, where two parameters, the fractional volume of 
extracellular free-water (FW) and cellular tissue FA (FA-t), were estimated and compared across 
the entire white matter skeleton between groups, and correlated with cognitive measures at 
baseline and following 12 weeks of antipsychotic treatment. Our results indicated lower FA across 
the whole brain in patients compared to healthy controls that overlap with significant increases in 
FW, with only limited decreases in FA-t. In addition, higher FW correlated with better 
neurocognitive functioning following 12 weeks of antipsychotic treatment. This is the first study to 
suggest that an extracellular water increase during the first-episode of psychosis, which may be 
indicative of an acute neuroinflammatory process, and/or cerebral edema may predict better 
functional outcome.
A. Introduction
Schizophrenia (SZ) is a chronic psychiatric disorder that affects almost 1% of the population 
(1). While the etiology of SZ is still unclear, it has been posited to be a disorder of 
“dysconnectivity,” such that many of the behavioral symptoms and cognitive deficits in SZ 
can be explained by aberrations in the communication of information among cortical areas 
(2,3). In recent years, increased focus has been placed on cerebral white matter connections 
because they are purported to play a central role in SZ pathophysiology (4). The 
involvement of white matter pathology is supported by postmortem and histological studies 
that identify abnormalities in myelin and myelin-related genes in patients with SZ (5,6).
The application of diffusion tensor imaging (DTI) has permitted the interrogation of 
microstructural properties of white matter in vivo (7). The most common finding in SZ is 
lower fractional anisotropy (FA) in the corpus callosum, and the majority of fronto-temporal 
fasciculi (8,9). Lower FA in patients has frequently been interpreted to reflect changes in the 
“integrity” of myelinated connections. There is a high degree of variability, however, in 
reported findings, likely due to the fact that DTI indices (e.g., FA) are sensitive to a range of 
biological pathologies, such as axonal degeneration, demyelination, or increases in 
extracellular water volume (10). The lack of specificity of FA necessitates the development 
of metrics to distinguish among white matter pathologies that may underlie the neurobiology 
of SZ.
A promising new development is Free Water Imaging, which uses a two-compartment model 
of water diffusion from diffusion-weighted images (DWIs)(11). This method increases the 
specificity of the traditional single-compartment model, DTI, by separating the contribution 
of freely diffusing extracellular water from water in the proximity of brain cells and their 
processes. Free Water Imaging calculates two parameters. The first, FW, which reflects the 
fractional volume of unrestricted free-water, has been proposed to serve as an indicator of 
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extracellular changes that are being driven by pathologies such as atrophy, cerebral edema, 
or neuroinflammation (11). The second is the residual diffusion signal from restricted/
hindered water, that is modeled as a diffusion tensor and termed fractional anisotropy of the 
“tissue” (FA-t), reflecting the microstructure of cells and their processes. By separating the 
extracellular free-water component from the “tissue” component, Free Water Imaging 
provides greater sensitivity to detect structural changes between groups through both 
measurements of extracellular pathology, as well as lowering the variability in the tissue-
related parameter, FA-t, comparing to the traditional FA metric (12).
Using the Free Water Imaging approach in a cohort of recent-onset schizophrenia patients 
we showed that frequently reported widespread reductions in FA (see reviews(8,9)) can be 
explained by significant increases in FW (13). Interestingly, there were only circumscribed 
reductions in FA-t in frontal lobe white matter (13), leading to the conclusion that 
individuals in the early stages of schizophrenia were exhibiting a global increase of FW, 
indicating extracellular changes, and not widespread myelin deterioration, as previously 
suggested (8,9). Evidence from recent PET studies describing increased levels of activated 
microglia and reactive astrocytes coupled with reports of greater levels of pro-inflammatory 
cytokines in blood or cerebrospinal fluid in patients have led to the hypothesis that these 
extracellular changes are consistent with a neuroinflammatory response (14–16). Moreover, 
these studies further suggest that such a response is present at earlier, more acute stages of 
schizophrenia, than widespread axonal degeneration, which has been demonstrated to be 
more pronounced at later stages of the disorder (17).
The primary goal of the current study was to investigate whether increases in extracellular 
FW would be observed among patients experiencing a first episode of psychosis studied 
early in the course of illness and prior to extensive pharmacologic intervention. Moreover, 
because the functional significance of the extracellular FW response remains largely 
unknown, an additional goal was to examine the neurocognitive and clinical correlates of 
FW in patients.
B. Methods
Subjects—Sixty-three patients experiencing a first-episode of psychosis (FEP) were 
recruited from the inpatient service at The Zucker Hillside Hospital in Glen Oaks, NY, and 
enrolled in an NIMH-funded double blind randomized controlled trial comparing 
aripiprazole (n=29) versus risperidone (n=34)(18). All patients had 2 weeks or less of 
cumulative lifetime exposure to antipsychotics prior to entry into the clinical trial. All 
patient (lifetime) diagnoses were based on the SCID for Axis I DSM-IV Disorders and 
included schizophrenia (undifferentiated = 25 and paranoid = 15), schizophreniform disorder 
(n=15), schizoaffective disorder (n=1), or psychosis NOS (n=7). On average, patients had a 
total lifetime exposure of 6.3 (SD = 7.3) days of antipsychotic treatment prior to the baseline 
scan and had received their MRI exam within an average of three days (range = −23 to 30 
days) of entry into the clinical trial. Twenty-one patients were antipsychotic drug-naïve at 
the time of the baseline scan. Mean age at first psychotic symptoms was 19.1 years (SD = 
4.6); data were unavailable for three patients.
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We recruited 70 healthy volunteers from advertisements to match the demographic 
distributions of patients. Exclusion criteria for healthy subjects included the presence of any 
lifetime history of a major mood or psychotic disorder as determined by clinical interview 
using the SCID-NP. Exclusion criteria for all study participants included MR imaging 
contraindications, and any serious medical disorder that could affect brain functioning or 
mental retardation.
This study was approved by the local Institutional Review Board and written informed 
consent was obtained from all study participants or their parents in the case of minors. All 
minors provided written informed assent to participate in the study.
Treatment Trial Antipsychotic Titration Schedule—Research psychiatrists followed 
a flexible dosing titration schedule. The initial daily dose for patients in the treatment trial 
was 5 mg for aripiprazole and 1 mg for risperidone, which was increased after three days of 
treatment with further adjustments made every 1–3 weeks until the patient improved, 
developed side effects that precluded a dose increase, or reached a maximum daily dose of 
30 mg of aripiprazole or 6 mg of risperidone. Patients were not allowed to receive 
antidepressants, mood stabilizers, or any other psychotropic medication.
Clinical Assessments—Patients completed the 18-item Brief Psychiatric Rating Scale – 
Anchored version (BPRS-A(19)) and we derived a total score by summing all items. The 
average Brief Psychiatric Rating Scale Score was 43.6 (SD = 8.6) at the time of baseline 
scanning and 27.7 (SD = 8.1) at follow-up.
Cognitive Assessments—We administered the MATRICS Consensus Cognitive Battery 
(MCCB) to patients at baseline and following 12-weeks of antipsychotic treatment. An 
overall score was computed as the average of the individual domains. At baseline, of the 
total 63 FEP patients included in this study, 57 FEP patients (43M/14F) completed the entire 
MCCB, while six FEP patients (3M/3F) did not. At the 12-week follow-up, of the 57 that 
completed the entire baseline MCCB, 39 FEP patients (28M/11F) returned and completed 
the entire MCCB, while 18 FEP patients (15M/3F) did not. We did not detect any significant 
differences in baseline values of age, sex, handedness, years of education, total BPRS score, 
and global ratings of negative symptoms between individuals with and without NP data at 
the 12-week time point.
Diffusion MR Procedures—Diffusion MR scans were acquired at the North Shore 
University Medical Center on a GE 3T HDx scanner. A total of 36 diffusion weighted 
images (DWIs) were obtained from each subject at baseline, including 31 volumes with 
diffusion gradients applied along 31 non-parallel directions with b = 1000 s/mm2 and, and 5 
volumes without diffusion weighting (b = 0). Each volume consisted of 51 contiguous 2.5 
mm axial slices acquired parallel to the anterior-posterior commissural line using a ramp 
sampled, spin-echo, single shot echo-planar imaging method (TR = 14000ms, TE = 
<84.8ms, matrix = 128x128, FOV = 240mm).
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Image Analysis
Free Water Imaging—The Free Water Imaging analysis pipeline has been previously 
described (13,17). Briefly, diffusion-weighted images (DWIs) were corrected for motion and 
eddy-current artifacts by means of affine registration with a b=0 reference volume (FLIRT, 
FSL, Oxford) as in our prior work (13,17) and subsequently masked to exclude non-brain 
areas. We excluded 7 subjects with high motion from analysis (>2 SD from the mean)(11).
FW maps were created by fitting aligned DWIs with a two-compartment model comprised 
of a free-water compartment and a “tissue” compartment as described previously (11). 
Briefly, the free-water compartment extracts the contribution of water molecules that diffuse 
freely in the extracellular space, quantified by a single parameter called FW, which stands 
for the fractional volume of free-water. The second compartment describes the behavior of 
water molecules that are affected by proximity to cells, and are modeled utilizing a diffusion 
tensor. This produces two voxel-wise maps, one representing FW and one representing the 
FA values that are corrected for FW (FA-t).
White Matter Processing—We employed the tract-based spatial statistics (TBSS) 
pipeline (20) and the FA target image and skeleton that was created by the Enhanced 
Neuroimaging Genetics by Meta Analysis (ENIGMA) DTI Working Group at the University 
of Southern California, all of which are publicly available (http://enigma.ini.usc.edu/
ongoing/dti-working-group)(21). We utilized the ENIGMA processing stream to allow for 
greater generalizability of results across studies, including an ongoing, multi-site meta-
analysis of diffusion data from schizophrenia patients across 22 sites (22). Using this 
pipeline, we projected the FA, FA-t, and FW maps onto the skeleton to perform statistical 
analyses.
Statistical Analysis
Group comparisons were performed using a nonparametric permutation-based test 
(Randomise, FSL) with a threshold free cluster enhancement (TFCE) and family-wise error 
correction (23,24). The data were then tested against an empirical null distribution, which 
was generated by 5000 permutations for each contrast, resulting in statistical maps that are 
corrected for multiple comparisons across the whole brain and significance at a threshold of 
p < 0.05. Age and sex were included as covariates. As there was no significant difference 
between groups for the calculated motion parameter (t = 0.884, p = 0.3781; Means: FEP = 
0.53; HC = 0.52) it was not included as a covariate. For the purpose of investigating 
correlates of diffusion signal, significant clusters were averaged to create a single cluster 
mean for FA-t and FW for each subject.
One additional set of voxel-wise statistical comparisons was computed utilizing the 
previously mentioned nonparametric permutation-based test (Randomise, FSL) to determine 
the possible effects of medication on our findings. We compared FA-t and FW values 
between medicated FEP patients and medication-naïve FEP patients with age and sex as 
covariates.
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We correlated baseline averaged FA, FA-t and FW values for patients with the Overall score 
on the MCCB at baseline and 12 weeks following treatment. If the Overall MCCB score was 
significantly correlated with FA, FW or FA-t at baseline or 12 weeks, we then examined the 
individual domains and corrected for multiple comparisons (Bonferroni adjusted 
significance threshold: p < 0.007). Baseline averaged FA, FA-t and FW values in FEP 
patients were also correlated with scores on the BPRS at baseline and 12 weeks.
To explore sex effects in both healthy controls (HC) and FEP patients, we conducted a post-
hoc analysis where we divided the entire sample into four groups: HC Females (n=24), HC 
Males (n=46), FEP Females (n=17), and FEP Males (n=46). We calculated a one-way 
ANCOVA to test the main effect of group while controlling for age. We utilized Tukey’s 
Honest Significant Difference test to calculate post-hoc pairwise comparisons between 
means of each group with p-values that were corrected for the total number of comparisons 
to the confidence level of 0.95 (p < 0.05) using family-wise error rates.
C. Results
There were no significant differences between FEP and the HC in distributions of age, sex, 
and handedness, but groups did differ in education (Table 1). There were no significant 
differences in demographic variables between patients treated with aripiprazole versus 
risperidone (18).
C1. Extent and Nature of Diffusion Changes in First-Episode Schizophrenia Patients
The FEP group showed significantly (p < 0.05) lower FA extending over most of the white 
matter skeleton compared to controls (Figure 1). A significant globalized increase in FW (p 
< 0.05) in FEP compared to HC was also observed (Figure 1). As illustrated in Figure 1, 
there is almost complete overlap between the regions with lower FA and those with higher 
FW in FEP compared to HC, suggesting that FA changes can be mostly explained by 
alterations in the extracellular free-water compartment. In contrast, the FA-t voxel-wise 
analysis produced only circumscribed differences between FEP and HC. Significant 
reductions (p < 0.05) in FA-t in FEP were found in the body and genu of the corpus 
callosum and the left superior and posterior corona radiata as well as the left superior 
longitudinal fasciculus (Figure 1).
We compared the FW and FA-t values between medicated FEP (n=42) and medication-naïve 
FEP (n=21) patients and found no significant differences in either FW or FA-t (p > 0.05), 
suggesting that medication status at baseline does not significantly contribute to the 
observed group differences.
C2. Cognitive Correlates of Extracellular FW Increase in FEP Patients
At baseline, FA, FA-t and FW in the FEP were not related to overall MCCB performance. 
However, baseline FW values in patients showed a significant positive correlation with 
overall MCCB performance 12 weeks following treatment (Pearson’s r = 0.4712, p = 
0.0025) (Figure 2). Of the seven domains, all but the social cognition domain demonstrated a 
positive correlation with baseline FW values; however, only two domains survived 
Bonferonni correction (see Supplementary Figure 1): Working Memory (Pearson’s r = 
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0.4287, p = 0.0065), and Verbal Memory (Pearson’s r = 0.5159, p = 0.0008). This finding 
was unique to FW, as FA and FA-t at baseline did not predict performance on the overall 
MCCB. Baseline average FA, FW and FA-t values did not correlate significantly with BPRS 
scores at either baseline or 12 weeks.
C4. Sex Effects
The results of the exploratory one-way ANCOVA reveal a significant group difference in 
FW (F = 9.32, p < 0.0001; Figure 3). Post-hoc pairwise comparisons using Tukey’s HSD for 
FW values (Table 2) showed significant differences for the following comparisons: FEP 
Females-HC Females (p = 0.0004), FEP Males-HC Males (p = 0.02), FEP Females-FEP 
Males (p = 0.04) and FEP Females-HC Males (p < 0.0001). There were no significant 
correlations between FW and MCCB overall scores at baseline for either the male or female 
FEP patients. FW values in both male and female FEP patients correlated significantly with 
overall MCCB score at the 12-week follow-up (Male FEP r = 0.5247, Female FEP r = 
0.4569) with no significant difference between the correlations (z = −0.22, p = 0.82).
D. Discussion
We report higher FW values in FEP patients compared to HC that are widespread, 
encompassing multiple regions that have been previously implicated in the neurobiology of 
schizophrenia. In contrast to widespread FW changes, we observed reductions in FA-t in 
FEP patients only in circumscribed segments of the corpus callosum, left corona radiata, and 
left superior longitudinal fasciculus. Among patients, higher FW was associated with better 
cognitive functioning following 12 weeks of antipsychotic treatment.
Our study demonstrates that lower FA in FEP, a finding previously reported in multiple 
studies, is likely related to significant increases in FW (8,9). This result is consistent with 
our prior findings in recent-onset schizophrenia patients (13) and indicates that extracellular 
brain changes could serve as an indicator of early stage psychosis. One possible explanation 
for higher FW at the first-episode of psychosis is a neuroinflammatory response, as 
extracellular water volume is expected to be increased in neuroinflammatory states due to 
the accumulation of water in the extracellular space (e.g., edema). Although we 
acknowledge that other possible mechanisms could lead to greater extracellular water 
volume, the neuroinflammation hypothesis is supported by considerable evidence that 
abnormalities in the immune response may play a role in the pathophysiology of 
schizophrenia. Data from diverse fields, including genetic (25–28), blood serology (29–31), 
and postmortem studies (32,33) support the “inflammation hypothesis.” Moreover, a recent 
genome-wide analysis implicated immune-related pathways as a principal risk factor in 
schizophrenia (28) and studies of FEP patients report greater pro-inflammatory cytokines 
and cytokine receptors (16,34,35).
While an increasing number of studies have identified the presence of a possible 
neuroinflammatory response in schizophrenia, little is known regarding its functional 
significance, especially early in psychosis. A prior study indicated that interleukin-6 levels 
were negatively correlated with FA highlighting a potential mechanism for immune system 
abnormalities in the neurobiology of white matter dysfunction in early-course clinically 
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stabilized patients with schizophrenia (Prasad et al 2015)(36). Bulzacka and colleagues 
(2016) also identified abnormally high C-reactive protein (CRP) levels in a subgroup of 104 
chronic patients that were associated with impaired general intellectual ability (37). 
Similarly, Dickerson and authors (2007) reported that higher CRP levels were associated 
with worse functioning on the Repeatable Battery for the Assessment of Neuropsychological 
Status compared to patients with lower CRP levels (38).
We demonstrate that greater FW during the first-episode of psychosis has a positive 
relationship with cognitive functioning following 12 weeks of antipsychotic treatment. This 
correlation was uniquely related to FW, as reductions in FA-t observed at baseline in FEP 
patients were unrelated to cognitive functioning. The finding of an increased, rather than a 
decreased, FW response predicting better neurocognitive outcome may seem paradoxical 
given that a majority of studies portray brain neuroinflammation in SZ as detrimental (39–
42). It is important to note, however, that while chronic inflammation is indeed a central part 
of the majority of neurodegenerative brain disorders, acute neuroinflammatory responses are 
usually intended to promote healing in cases of brain injury (43). Few studies have 
investigated correlates of the neuroinflammatory response early in the course of illness in 
relation to neurocognitive functioning. Taken together, our findings are consistent with the 
hypothesis that the ability to mount an inflammatory response at the onset of psychosis may 
portend a better neurocognitive outcome following antipsychotic treatment. Over the long 
term, however, it is conceivable that an inability to resolve this response, and/or the 
cumulative effect of chronic treatment with antipsychotic medications, may lead to white 
matter abnormalities and neuropsychological dysfunction. Additionally, we found that 
correlations between FW and MCCB domains were most robust for working and verbal 
memory. These domains of functioning have consistently been demonstrated to be the most 
impaired in schizophrenia (44,45) and have been identified as the most promising 
endophenotypes for SZ because they are also observed among unaffected relatives (45,46).
The relatively large number of female FEP offered the opportunity to explore sex effects. 
Female FEP exhibited significantly increased FW values compared to female HC, male HC, 
and male FEP. FEP males exhibited significant differences in FW when compared to male 
healthy controls; however not to the same degree as the female FEP. Our FW findings 
converge with a recent study reporting high levels of C-reactive protein (hsCRP), an acute 
phase response immune marker in schizophrenia patients (47). These investigators 
demonstrated greater levels of hsCRP in female patients compared to both female and male 
controls, as well as male schizophrenia patients (47), suggesting there might be an increased 
inflammatory response in the female patients’ brains relative to male patients’ brains. This is 
particularly intriguing because much of the previous literature indicates that although males 
and females have a similar incidence and prevalence of schizophrenia, females patients tend 
to have lower relapse rates and higher pre- and post-morbid functioning (48). Based on the 
results of our study, and the preceding study by Joseph and colleagues (47), an important 
focus of future studies would be the further examination of sex differences in these 
parameters.
There are several limitations of our study. The proportion of male and female participants 
was not equal and larger sample sizes will be required to confirm findings of sex differences. 
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Similarly, although we found no significant difference between patients minimally treated 
with antipsychotics compared to antipsychotic drug-naïve patients in either FW or FA-t, 
suggesting that short-term antipsychotic medication is not influencing the FW measure in 
first-episode patients, these findings should be confirmed longitudinally in patients receiving 
therapeutic dosages. Although no significant differences in baseline demographic or 
cognitive variables were found between patients that remained in the study and those that 
dropped out, we acknowledge the possibility that differential attrition could still conceivably 
affect the results presented herein. Moreover, in the absence of longitudinal imaging data, it 
is difficult to draw definitive conclusions about underlying biological correlates of the 
observed cognitive outcomes in patients. Atypical antipsychotics have been shown to have 
anti-inflammatory effects, which could be mediating the observed outcomes (16,49). As we 
report no significant association between FW and neurocognitive performance at baseline 
we conclude that greater baseline FW and subsequent antipsychotic treatment is associated 
with better cognitive performance.
We must also acknowledge that FW should be considered only a proxy for 
neuroinflammation because it is an indirect measures of the neuroinflammatory response, 
i.e., increased extracellular fractional volume (50). There are other possible underlying 
biological pathologies previously reported in schizophrenia patients that could explain the 
findings presented herein. These include pathologies such as decreased neuronal size (51), 
which may be related to the reductions in FA-t, or atrophy due to excessive synaptic pruning 
(52), which may contribute to the increased FW. Such pathology may, however, be more 
likely identified in the gray matter and in patients at more chronic stages of illness (51,52). 
Also, we note that the correlation between average whole brain FA and average whole brain 
FW was r = −0.78. In the context of the Free Water Imaging model, we expect lower FA in 
regions with higher FW in the absence of any reduction in FA-t. If there is a reduction in FA-
t, without concomitant changes in FW, this would also be reflected as lower FA in which 
case FW would not be correlated with FA. Therefore, it is important to acknowledge that FA 
and FW should not be simply construed as “mirror opposites.” Thus, the correlation between 
these two measures suggests that the observed abnormality is related to an increase in 
extracellular water, but not restricted/hindered water.
In summary, we find that lower FA in FEP can be explained primarily by greater FW, a 
potential proxy for an acute neuroinflammatiory response. We present evidence that higher 
FW at the first-episode of psychosis predicts better cognitive outcome following 12 weeks of 
antipsychotic treatment. Additionally, we find that short-term antipsychotic treatment is not 
related to extracellular FW increases or reductions in FA-t at baseline. Finally, we show that 
sex can have a significant influence on FW in first-episode schizophrenia patients.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Widespread significant reductions in FA (A) appear to considerably overlap with significant 
global increases in FW (B). Only limited reductions in FA-t are observed in first-episode 
patients (C). No differences between medicated and medication- naïve patients were found 
for FA, FW, or FA-t.
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Figure 2. 
Average baseline FW values in first-episode patients show a significant positive correlation 
with overall performance on the MCCB 12 weeks following antipsychotic treatment. This 
suggests that greater FW values at the time of presentation of frank psychosis predict better 
neurocognitive functioning 12 weeks later. This finding was unique to FW, as baseline FA-t 
was not correlated with MCCB scores at either baseline or 12 weeks following treatment.
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Figure 3. 
Our results show a significant influence of sex on the FW response at baseline. FW values 
were significantly greater in female first-episode patients (n = 17) compared to male first-
episode patients (n = 46) as well as both male and female healthy controls. Male first-
episode patients also exhibited significantly greater FW values when compared to healthy 
controls. There was no significant difference in the correlations between the overall MCCB 
scores and FW values when comparing male and female FEP patients (See Table 2).
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Table 1
Healthy Controls
Mean (SD)
First-Episode Patients
Mean (SD)
P-value
Total Sample (N) 70 63 0.47
 Males 46 46
 Females 24 17
Age (years) 21.51 (5.01) 21.38 (4.89) 0.8756
Edinburgh 0.6986 (0.47) 0.6967 (0.44) 0.9815
Education (years) 13.33 (2.69) 12.32 (1.91) 0.0129
Medication Status
 Medicated 30 M/12 F
 Medication-Naïve 16 M/5 F
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Table 2
Pairwise Comparison of Mean for Sex by Diagnosis Groups: Tukey’s HSD
FW Difference in Means Adjusted P-value
FEP-F vs. HC-F 0.031 0.0004*
FEP-M vs. HC-M 0.014 0.023*
FEP-F vs. FEP-M 0.019 0.035*
FEP-F vs. HC-M 0.033 0.00002*
HC-F vs. FEP-M −0.012 0.168
HC-F vs. HC-M 0.002 0.988
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